The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Friday, August 14, 2026

Subject of the day

BSX

Concerning the House

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

United States · www.bostonscientific.com

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$16.75B+4.6%
Gross profit$11.49B+4.6%
Operating income$2.60B+72.7%
Cash from ops$3.44B+9.2%
Quotation

$51.69

+0.27 (+0.5%)

52w hi$108.14
52w lo$42.63
Vol15.63M
As ofAug 13
The Verdict

Sell

Our score -0.60

Short-1.02
Medium-0.54
Long+0.10

computed 2026-08-13

By the Numbers

Boston Scientific Corporation

Healthcare · Medical Devices

Market cap$74.91B
Enterprise value$86.85B
Trailing P/E20.93x
Forward P/E15.03x
EV / EBITDA15.21x
P / S (ttm)3.57x
Profit margin17.5%
Return on equity15.3%
Revenue growth+7.5%
Earnings growth+15.1%
Debt / equity50.15
Risk Metrics
Beta vs SPX0.56
Corr SPX0.30
Annual vol30.3%
Annual ret-14.2%
Sharpe-0.47
Max DD-60.6%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental+0.30
Sector+0.12
Technical-0.58
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$51.57$52.33$51.23$51.6915.63M
Aug 12$50.50$51.74$50.02$51.4220.67M
Aug 11$50.27$51.50$50.13$51.1913.45M
Aug 10$49.54$50.82$49.54$50.4618.99M
Aug 7$49.50$50.12$49.06$49.3111.45M